AbbVieABBV

AbbVieABBV

Revenue: is the business selling more than it used to?

$61.2B+9% YoYFY 2025

→Revenue reached $61.2B in 2025, compounding +2% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $64.4B, ahead of the last full year.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

Net income: how much of that revenue becomes profit?

$4.2B−1% YoYFY 2025

→Net income was $4.2B in 2025, compounding -29% a year over three years. Earnings per share moved +68% over the last twelve months. Trailing twelve-month profit stands at $6.3B.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

How fast is it growing, year by year?

+8.6%revenue growth, FY 2025

→Revenue grew +9% in 2025 against a five-year average of +6%. Earnings went the other way (-1%) even as sales grew, so margins compressed: costs rose faster than revenue.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

Revenue per share: is your slice growing as fast as the company?

$34.50revenue per share, FY 2025

→Revenue per share reached $34.50 in 2025, compounding +2% a year - in line with ABBV's own +2%, so the share count is not distorting your slice. Free cash flow per share stands at $10.05.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

Free cash flow: what is left in real cash after everything?

$17.8B−0% YoYFY 2025

→Free cash flow was $17.8B in 2025, compounding -10% a year since 2022. The trailing twelve months stand at $18.2B.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

How much of every sales dollar ends up as free cash?

→29 cents of every sales dollar became free cash in 2025, down 13 points since 2022.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

What does staying competitive cost, per dollar of sales?

→The biggest claim on each sales dollar is capital spending, at 2% of revenue (stock compensation 2%). That share has risen since 2022, so the cost of competing is climbing.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

When sales grow, do profits grow faster?

→Operating profit outgrew revenue in only 2 of the last 5 years. Costs are growing roughly in step with the business, so scale isn't yet paying for itself.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

Margins: of every $1 of sales, how much survives each cost layer?

→Operating margin compressed 7 points to 25% since 2022. After everything, 7 cents of each sales dollar reaches net profit. ABBV doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

What does it earn on the money it uses?

→Return on capital needs both a profit and an equity base; one of them isn't available here.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

What has the market paid for ABBV over time?

72.1xP/E today

→At 72.1x earnings, the market is paying +284% more than ABBV's own 11-year median of 18.8x. Expectations are elevated, so more has to go right to justify the price.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

What cash return does the business throw off per dollar of market value?

4.0%FCF yield today

→Every dollar of market value currently buys 4.0% of annual free cash flow, less than its 11-year median of 11.4% - you are paying up for the same cash.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

Could it handle its debt if things went wrong?

→Debt of $62.5B sits against $6.6B of cash. Earnings cover interest 5.8 times - adequate, with less room than it looks in a downturn.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

Is the company's own capital growing?

→Shareholders' equity is negative at $-5.9B: liabilities exceed assets. Usually the mark of heavy buybacks or accumulated losses, and always worth understanding which.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

How much goes back, and how much leaks out as stock comp?

→Shareholders received $980M in buybacks and $11.7B in dividends in 2025. Stock compensation issued $955M of new shares in the same year, offsetting 8% of that.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

How fast is your ownership being diluted - or concentrated?

→The share count shrank 0.0% in 2025, averaging 0.1% a year over three years. Buybacks are concentrating your ownership: the same business, split fewer ways.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

Is the dividend cheque growing?

→The dividend per share reached $6.57 in 2025, compounding +7% a year since 2020.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

Can it afford the dividend?

→The dividend consumed 276% of profit and 65% of free cash flow in 2025. That is a thin cushion: a bad year would put the payment under real pressure.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

Does ABBV earn more on its capital than that capital costs?

→ABBV earns 16.6% on the capital it employs, comfortably above the 10% most investors treat as the cost of capital. It was 16.6% in 2022, so the trend is flat, and the pace is picking up.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

ABBV has issued or retired shares - did shareholders end up better off?

→ABBV issued +12% more shares from 2011 to 2025, but revenue per share still rose +212%. The dilution bought more growth than it cost existing holders.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30

AbbVieABBV

Are the people running it buying or selling?

→Insiders sold $19M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 54 filings were grants, option exercises or tax withholding, which say nothing either way.

Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30